Clinical trial
DOS [Dosing Optimization Study]: Open-label, Single-arm, Proof-of-Concept Dosing Study of Afrezza® in Adult Subjects 18 Years and Older With Type 1 or Type 2 Diabetes Mellitus
NCT04849845 is registered in ClinicalTrials.gov with Mannkind Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- DOS [Dosing Optimization Study]: Open-label, Single-arm, Proof-of-Concept Dosing Study of Afrezza® in Adult Subjects 18 Years and Older With Type 1 or Type 2 Diabetes Mellitus
- Lead sponsor
- Mannkind Corporation
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- April 9, 2021
- Completion date
- May 28, 2021
- Enrollment
- 20 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.